ViroPharma Incorporated (VPHM)

[surf1944]

ViroPharma Incorporated Reports Second Quarter 2008 Financial Results
Wednesday July 30, 7:46 am ET
- Company Achieves Record Vancocin(R) Net Sales; Increases Full Year Guidance for 2008 -

EXTON, Pa., July 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM - News) reported today its financial results for the second quarter and six-months ended June 30, 2008.

Key events since March 31, 2008 include:

Development:

-- Completed enrollment in Phase 3 study of maribavir in stem cell transplant (SCT) patients;

-- Announced intent to present top-line maribavir Phase 3 SCT data in the first quarter of 2009;

-- Announced intent to file the initial New Drug Application (NDA) in the U.S., Marketing Authorization Application (MAA) in Europe, and New Drug Submission (NDS) in Canada for maribavir in SCT patients in the third quarter of 2009;

-- Complete clinical trial results from maribavir Phase 2 study in stem cell transplant patients were published in the June 1 issue of the scientific journal Blood; and

-- Patient enrollment continued in Phase 3 study of maribavir in solid organ (liver) transplant patients.

Operational:

-- Net sales of Vancocin achieved a record $65 million;

-- Research and development expenses increased by 106 percent over the second quarter of 2007, primarily driven by investments in maribavir and NTCD; and

-- Selling, general and administrative expenses increased 94 percent over the second quarter of 2007 due to increased investments in our European operations, our Vancocin sales force, additional medical education activities and increased marketing efforts.

Business Development:

http://biz.yahoo.com/prnews/080730/new042a.html?.v=1